Australija - engleski - Department of Health (Therapeutic Goods Administration)

actavis pty ltd - irinotecan hydrochloride -

Australija - engleski - APVMA (Australian Pesticides and Veterinary Medicines Authority)

virbac - pyriproxyfen(3g/l)+permethrin 40:60(400g/l) - topical solution/suspension - insecticide - dog | bitch | castrate | puppy - brown dog tick | cat flea | flea | tick - except paralysis tick | ctenocephalides spp. | dog tick | ground fleas

Novi Zeland - engleski - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - irinotecan hydrochloride trihydrate 20 mg/ml;  ;   - solution for injection - 20 mg/ml - active: irinotecan hydrochloride trihydrate 20 mg/ml     excipient: hydrochloric acid lactic acid sodium hydroxide sorbitol water for injection

Novi Zeland - engleski - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - irinotecan hydrochloride trihydrate 20 mg/ml - solution for injection - 20 mg/ml - active: irinotecan hydrochloride trihydrate 20 mg/ml excipient: hydrochloric acid lactic acid sodium hydroxide sorbitol water for injection - dbl™ irinotecan injection concentrate is indicated as a component of first line treatment of patients with metastatic carcinoma of the colon or rectum. irinotecan injection concentrate is also indicated for patients with metastatic carcinoma of the colon or rectum whose disease has recurred or progressed following initial therapy.

Novi Zeland - engleski - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - irinotecan hydrochloride trihydrate 20 mg/ml ((equivalent to 17.33 mg irinotecan));   - solution for infusion - 20 mg/ml - active: irinotecan hydrochloride trihydrate 20 mg/ml ((equivalent to 17.33 mg irinotecan))   excipient: hydrochloric acid lactic acid sodium hydroxide sorbitol water for injection - irinotecan hydrochloride trihydrate injection is indicated as a component of first-line therapy for patients with metastatic carcinoma of the colon or rectum, in combination with 5fu/leucovorin. irinotecan hydrochloride trihydrate injection is also indicated for patients with metastatic carcinoma of the colon or rectum whose disease has recurred or progressed following initial therapy.

Novi Zeland - engleski - Medsafe (Medicines Safety Authority)

teva pharma (new zealand) limited - irinotecan hydrochloride trihydrate 100mg; irinotecan hydrochloride trihydrate 100mg - concentrate for injection - 100 mg - active: irinotecan hydrochloride trihydrate 100mg excipient: lactic acid sodium hydroxide sorbitol water for injection active: irinotecan hydrochloride trihydrate 100mg excipient: hydrochloric acid lactic acid sodium hydroxide sorbitol water for injection - irinotecan actavis is indicated as a component of first line therapy for patients with metastatic carcinoma of the colon or rectum. irinotecan actavis is also indicated for patients with metastatic carcinoma of the colon or rectum whose disease has recurred or progressed following initial therapy.

Novi Zeland - engleski - Medsafe (Medicines Safety Authority)

teva pharma (new zealand) limited - irinotecan hydrochloride trihydrate 40mg; irinotecan hydrochloride trihydrate 40mg - concentrate for injection - 40 mg - active: irinotecan hydrochloride trihydrate 40mg excipient: lactic acid sodium hydroxide sorbitol water for injection active: irinotecan hydrochloride trihydrate 40mg excipient: hydrochloric acid lactic acid sodium hydroxide sorbitol water for injection - irinotecan actavis is indicated as a component of first line therapy for patients with metastatic carcinoma of the colon or rectum. irinotecan actavis is also indicated for patients with metastatic carcinoma of the colon or rectum whose disease has recurred or progressed following initial therapy.

Novi Zeland - engleski - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - irinotecan hydrochloride trihydrate 20 mg/ml;   - solution for injection - 20 mg/ml - active: irinotecan hydrochloride trihydrate 20 mg/ml   excipient: lactic acid sodium hydroxide sorbitol water for injection - irinotecan ebewe is indicated for the first line treatment of patients with metastatic carcinoma of the colon or rectum, in combination with 5fu/leucovorin. irinotecan ebewe is also indicated for patients with metastatic carcinoma of the colon or rectum whose disease has recurred or progressed following initial therapy.

Australija - engleski - Department of Health (Therapeutic Goods Administration)

baxter healthcare pty ltd - irinotecan hydrochloride trihydrate, quantity: 100 mg - injection, concentrated - excipient ingredients: sodium hydroxide; lactic acid; water for injections; hydrochloric acid; sorbitol - irinotecan hydrochloride is indicated as a component of first-line therapy for patients with metastatic carcinoma of the colon or rectum. irinotecan hydrochloride is also indicated for patients with metastatic carcinoma of the colon or rectum whose disease has recurred or progressed following initial therapy.

Australija - engleski - Department of Health (Therapeutic Goods Administration)

baxter healthcare pty ltd - irinotecan hydrochloride trihydrate, quantity: 40 mg - injection, concentrated - excipient ingredients: water for injections; lactic acid; sorbitol; hydrochloric acid; sodium hydroxide - irinotecan hydrochloride is indicated as a component of first-line therapy for patients with metastatic carcinoma of the colon or rectum. irinotecan hydrochloride is also indicated for patients with metastatic carcinoma of the colon or rectum whose disease has recurred or progressed following initial therapy.